Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 1c, Reaffirms FY12 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $5.57 --0%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
SICP, MNSB, CFFI, More
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $110.5 million versus the consensus estimate of $106.49 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Reiterates Hold Rating on Myriad Genetics (MYGN)
- PG&E Corp. (PCG) Misses Q3 EPS by 1c, misses on revenue
- Spotify Q3 earnings preview: softer profit expected amid weaker margins
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
